FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2806551567> ?p ?o ?g. }

• W2806551567 abstract "In 2010, the Clinical Laboratory and Standards Institute recommended a 3-fold lowering of ceftriaxone breakpoints to 1 mcg/mL for Enterobacteriaceae. Supportive clinical data at the time were from fewer than 50 patients. We compared the clinical outcomes of adults with Enterobacteriaceae bloodstream infections treated with ceftriaxone compared with matched patients (with exact matching on ceftriaxone minimum inhibitory concentrations [MICs]) treated with extended-spectrum agents to determine if ceftriaxone breakpoints could be increased without negatively impacting patient outcomes.A retrospective cohort study was conducted at 3 large academic medical centers and included patients with Enterobacteriaceae bacteremia with ceftriaxone MICs of 2 mcg/mL treated with ceftriaxone or extended-spectrum β-lactams (ie, cefepime, piperacillin/tazobactam, meropenem, or imipenem/cilastatin) between 2008 and 2014; 1:2 nearest neighbor propensity score matching was performed to estimate the odds of recurrent bacteremia and mortality within 30 days.Propensity score matching yielded 108 patients in the ceftriaxone group and 216 patients in the extended-spectrum β-lactam group, with both groups well-balanced on demographics, preexisting medical conditions, severity of illness, source of bacteremia, and source control interventions. No difference in recurrent bacteremia (odds ratio [OR], 1.16; 95% confidence interval [CI], 0.49-2.73) or mortality (OR, 1.27; 95% CI, 0.56-2.91) between the treatment groups was observed for patients with isolates with ceftriaxone MICs of 2 mcg/mL. Only 6 isolates (1.6%) with ceftriaxone MICs of 2 mcg/mL were extended-spectrum β-lactamase (ESBL)-producing.Our findings suggest that patient outcomes are similar when receiving ceftriaxone vs extended-spectrum agents for the treatment of Enterobacteriaceae bloodstream infections with ceftriaxone MICs of 2 mcg/mL. This warrants consideration of adjusting the ceftriaxone susceptibility breakpoint from 1 to 2 mcg/mL, as a relatively small increase in the antibiotic breakpoint could have the potential to limit the use of large numbers of extended-spectrum antibiotic agents." @default.
• W2806551567 created "2018-06-13" @default.
• W2806551567 creator A5004403468 @default.
• W2806551567 creator A5018437292 @default.
• W2806551567 creator A5027736773 @default.
• W2806551567 creator A5030280540 @default.
• W2806551567 creator A5068120646 @default.
• W2806551567 creator A5073854380 @default.
• W2806551567 creator A5090134158 @default.
• W2806551567 date "2018-06-01" @default.
• W2806551567 modified "2023-09-24" @default.
• W2806551567 title "Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?" @default.
• W2806551567 cites W1945945803 @default.
• W2806551567 cites W2030341319 @default.
• W2806551567 cites W2096452676 @default.
• W2806551567 cites W2106307190 @default.
• W2806551567 cites W2113625735 @default.
• W2806551567 cites W2121560052 @default.
• W2806551567 cites W2127429285 @default.
• W2806551567 cites W2144772071 @default.
• W2806551567 cites W2156806600 @default.
• W2806551567 cites W2161342683 @default.
• W2806551567 cites W2163832044 @default.
• W2806551567 cites W2769199871 @default.
• W2806551567 doi "https://doi.org/10.1093/ofid/ofy139" @default.
• W2806551567 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6022551" @default.
• W2806551567 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29992175" @default.
• W2806551567 hasPublicationYear "2018" @default.
• W2806551567 type Work @default.
• W2806551567 sameAs 2806551567 @default.
• W2806551567 citedByCount "3" @default.
• W2806551567 countsByYear W28065515672019 @default.
• W2806551567 countsByYear W28065515672020 @default.
• W2806551567 crossrefType "journal-article" @default.
• W2806551567 hasAuthorship W2806551567A5004403468 @default.
• W2806551567 hasAuthorship W2806551567A5018437292 @default.
• W2806551567 hasAuthorship W2806551567A5027736773 @default.
• W2806551567 hasAuthorship W2806551567A5030280540 @default.
• W2806551567 hasAuthorship W2806551567A5068120646 @default.
• W2806551567 hasAuthorship W2806551567A5073854380 @default.
• W2806551567 hasAuthorship W2806551567A5090134158 @default.
• W2806551567 hasBestOaLocation W28065515671 @default.
• W2806551567 hasConcept C126322002 @default.
• W2806551567 hasConcept C141071460 @default.
• W2806551567 hasConcept C156957248 @default.
• W2806551567 hasConcept C167135981 @default.
• W2806551567 hasConcept C17923572 @default.
• W2806551567 hasConcept C2776520383 @default.
• W2806551567 hasConcept C2777050379 @default.
• W2806551567 hasConcept C2777637488 @default.
• W2806551567 hasConcept C2778193466 @default.
• W2806551567 hasConcept C2778266534 @default.
• W2806551567 hasConcept C2778368673 @default.
• W2806551567 hasConcept C2779375183 @default.
• W2806551567 hasConcept C2779443120 @default.
• W2806551567 hasConcept C2779631663 @default.
• W2806551567 hasConcept C501593827 @default.
• W2806551567 hasConcept C523546767 @default.
• W2806551567 hasConcept C54355233 @default.
• W2806551567 hasConcept C71924100 @default.
• W2806551567 hasConcept C86803240 @default.
• W2806551567 hasConcept C89423630 @default.
• W2806551567 hasConcept C94665300 @default.
• W2806551567 hasConceptScore W2806551567C126322002 @default.
• W2806551567 hasConceptScore W2806551567C141071460 @default.
• W2806551567 hasConceptScore W2806551567C156957248 @default.
• W2806551567 hasConceptScore W2806551567C167135981 @default.
• W2806551567 hasConceptScore W2806551567C17923572 @default.
• W2806551567 hasConceptScore W2806551567C2776520383 @default.
• W2806551567 hasConceptScore W2806551567C2777050379 @default.
• W2806551567 hasConceptScore W2806551567C2777637488 @default.
• W2806551567 hasConceptScore W2806551567C2778193466 @default.
• W2806551567 hasConceptScore W2806551567C2778266534 @default.
• W2806551567 hasConceptScore W2806551567C2778368673 @default.
• W2806551567 hasConceptScore W2806551567C2779375183 @default.
• W2806551567 hasConceptScore W2806551567C2779443120 @default.
• W2806551567 hasConceptScore W2806551567C2779631663 @default.
• W2806551567 hasConceptScore W2806551567C501593827 @default.
• W2806551567 hasConceptScore W2806551567C523546767 @default.
• W2806551567 hasConceptScore W2806551567C54355233 @default.
• W2806551567 hasConceptScore W2806551567C71924100 @default.
• W2806551567 hasConceptScore W2806551567C86803240 @default.
• W2806551567 hasConceptScore W2806551567C89423630 @default.
• W2806551567 hasConceptScore W2806551567C94665300 @default.
• W2806551567 hasFunder F4320332161 @default.
• W2806551567 hasFunder F4320332163 @default.
• W2806551567 hasFunder F4320337355 @default.
• W2806551567 hasLocation W28065515671 @default.
• W2806551567 hasLocation W28065515672 @default.
• W2806551567 hasLocation W28065515673 @default.
• W2806551567 hasLocation W28065515674 @default.
• W2806551567 hasOpenAccess W2806551567 @default.
• W2806551567 hasPrimaryLocation W28065515671 @default.
• W2806551567 hasRelatedWork W1988148441 @default.
• W2806551567 hasRelatedWork W1993808329 @default.
• W2806551567 hasRelatedWork W2026693802 @default.
• W2806551567 hasRelatedWork W2027437475 @default.
• W2806551567 hasRelatedWork W2060997578 @default.
• W2806551567 hasRelatedWork W2101382361 @default.
• W2806551567 hasRelatedWork W2118519564 @default.

• next